Clinical trial · no report yet · Phase 3
COSMIC-313
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- NCT03937219 ↗
- Active not recruiting
- Exelixis
- 222 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 104 | |
| Podcasts | 65 | |
| YouTube | 52 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Cabozantinib; Nivolumab; Ipilimumab; Cabozantinib-matched placebo
- Arms
- Experimental Arm · Experimental
- Control Arm · Active comparator
- Enrollment
- 855
- Primary outcomes
- Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)
- Sponsor
- Exelixis
- Start
- Jun 25, 2019
- Primary completion
- Jan 31, 2022
- Results posted
- Yes
- Registry record
- NCT03937219 · updated Sep 10, 2025
Publications
linked from the registry- Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. PubMed 37163623
- Labriola MK, George DJ. Setting a new standard for long-term survival in metastatic kidney cancer. Cancer. 2022 Jun 1;128(11):2058-2060. doi: 10.1002/cncr.34177. Epub 2022 Apr 5. No abstract available. PubMed 35383907
- Mar N, Kaakour D, Rezazadeh Kalebasty A. Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges. JCO Oncol Pract. 2022 Mar;18(3):197-199. doi: 10.1200/OP.21.00446. Epub 2021 Sep 22. No abstract available. PubMed 34550754
- Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2. PubMed 33058158